Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2025, 7(1); doi: 10.25236/IJFM.2025.070111.

Mutation analysis of Mycoplasma pneumoniae A2063G and A2064G in children infected with Mycoplasma pneumoniae in Tai'an area

Author(s)

Xiaoli Li, Luohui Wang

Corresponding Author:
Luohui Wang
Affiliation(s)

Tai'an Maternal and Child Health Hospital, Tai'an City, Shandong Province, China

Abstract

Mycoplasma pneumoniae infection is a self-limiting disease, but if the infection is not treated in time, it can easily develop into severe pneumonia, bronchitis, asthma and community-acquired pneumonia, which seriously affects the health of the infected person. Macrolide antibiotics are the first choice for the treatment of Mycoplasma pneumoniae infection, and macrolide-resistant strains of Mycoplasma pneumoniae have been isolated in clinical practice. Patients infected with drug-resistant strains of Mycoplasma pneumoniae had significantly longer fever duration, hospitalisation time and fever duration after drug administration than sensitive strains. The aim of this study was to analyse the mutation of A2063G and A2064G drug-resistant gene loci in children with Mycoplasma pneumoniae infections admitted to Tai'an Maternal and Child Healthcare Hospital in the past two years, and to explore the epidemiological characteristics of these strains, so as to provide a basis for the prevention and treatment of Mycoplasma pneumoniae in children.

Keywords

Mycoplasma pneumoniae, Resistance genes, Mutations, Epidemiological features

Cite This Paper

Xiaoli Li, Luohui Wang. Mutation analysis of Mycoplasma pneumoniae A2063G and A2064G in children infected with Mycoplasma pneumoniae in Tai'an area. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 1: 70-74. https://doi.org/10.25236/IJFM.2025.070111.

References

[1] LENG M, YANG J, ZHOU J.Yhe molecular characteristics, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae in children[J].Front Pediatr, 2023, 11:1-9.

[2] Liu X, Jiang Y, Chen X, Li J, Shi D, Xin D. Drug Resistance Mechanisms of Mycoplasma pneumoniae to Macrolide Antibiotics[J].BioMed research international, 2014;2014.

[3] GUO D X, HU W J, WEI R, et al, Epidemiology and mech-anism of drug resistance of Mycoplasma pneumoniae in Bei-jing, China:a multicenter study[J].Bosn J Basic Med Sci, 2019, 19(3):288-296.

[4] JONES M C.Mycoplasma pneumonia[J].Practitioner, 1969, 203(218):751-9.

[5] KIM E K, YOUN Y S, RHIM J W, et, al.Epidemiological comparison of three Mycoplasma pneumonia epidemics in a single hospital over 10years[J].Korean J Pediatr, 2015, 58(5):172-7.

[6] JAIN S, WILLIAMS D J, ARNOLD S R, et al.Community-acquired pneumonia requiring hospitalization among U.S.children[J].N Engl J Med, 2015, 372(9):835-45. 

[7] CHALKER V, STOCKI, LITT D et, al.Increased detection of Mycoplasma pneumonia infections in children in England and Wales, October2011 to January2012[J].Euro Surveill, 2012, 17(6).

[8] LANATA M, WANG H, EVERHART K, et al.Macrolide-Resistant Mycoplasma pneumonia infections in children, Ohio, USA[J].Emerging infections diseases, 2021, 27(6):1588-97.